Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis

Annals of Neurology

Volumn 46, Issue 3, 1999, Pages 296-304

  Coles, Alasdair J ^a   Wing, Mark G ^a   Molyneux, Paul ^e   Paolillo, Andrea ^e   Davie, Charlie M ^e   Hale, Geoff ^c,d   Miller, David ^e   Waldmann, Hermann ^d   Compston, Alastair ^a,b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c Therapeutic Antibody Centre   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BRAIN SCINTISCANNING; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

EID: 0032882173     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199909)46:3<296::aid-ana4>3.0.co;2-%23     Document Type: Article

References (43)

1. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-451
2. Qin S, Cobbold SP, Pope H, et al. "Infectious" transplantation tolerance. Science 1993;259:974-977
3. Moreau T, Thorpe J, Miller D, et al. Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum. Lancet 1994;344:486]. Lancet 1994;344:298-301
4. Moreau T, Coles A, Wing M, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996;119:225-237
5. Charpentier B, Hiesse C, Lantz O, et al. Evidence that antihuman tumor necrosis factor monoclonal antibody prevents OKT3-induced acute syndrome. Transplantation 1992;54:997-1002
6. Ferran C, Dy M, Sheehan K, et al. Cascade modulation by anti-tumor necrosis factor monoclonal antibody of interferon-gamma, interleukin 3 and interleukin 6 release after triggering of the CD3/T cell receptor activation pathway. Eur J Immunol 1991;21:2349-2353
7. Paolillo A, Coles A, Molyneux P, et al. Quantitative MRI in patients with secondary progressive MS treated monoclonal antibody, Campath-1H. Neurology (In press)
8. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33: 1444-1452
9. Branch DR, Shah A, Guilbert LJ. A specific and reliable bioassay for the detection of femtomolar levels of human and murine tumor necrosis factors. J Immunol Methods 1991;143:251-261
10. Hay H, Cohen J. Studies on the specificity of the L929 cell bioassay for the measurement of tumour necrosis factor. J Clin Lab Immunol 1989;29:151-155
11. Losseff NA, Wang L, Lai HM, et al. Progressive cerebral atrophy in multiple sclerosis: a serial MRI study. Brain 1996;119: 2009-2019
12. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231
13. Youl BD, Turano G, Miller DH, et al. The pathophysiology of acute optic neuritis: an association of gadolinium leakage with clinical and electrophysiological deficits. Brain 1991;114:2437-2450
14. Davis FA, Schauf CL, Reed BJ, Kesler RL. Experimental studies of the effects of extrinsic factors on conduction in normal and demyelinated nerve. 1. Temperature. J Neurol Neurosurg Psychiatry 1976;39:442-448
15. Schauf CL, Davis FA, Sack DA, et al. Neuroelectric blocking factors in human and animal sera evaluated using the isolated frog spinal cord. J Neurol Neurosurg Psychiatry 1976;39: 680-685
16. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997;120:2149-2157
17. Frequin ST, Lamers KJ, Barkhof F, et al. Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. Acta Neurol Scand 1994;90:105-110
18. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987;50:511-516
19. Van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996;47:1531-1534
20. Elliott MJ, Maini RN, Feldmann M, et al. Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet 1994;344: 1125-1127
21. Elliott MJ, Maini RN, Feldmann M, et al. Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344:1105-1110
22. Stone LA, Frank JA, Albert PS, et al. Characterization of MRI response to treatment with Interferon beta-Ib: contrast-enhancing MRI lesion frequency as a primary outcome measure. Neurology 1997;49:862-869
23. Rudge P, Miller D, Crimlisk H, Thorpe J. Does Interferon beta cause initial exacerbation of multiple sclerosis? Lancet 1995; 345:580 (Letter)
24. Stone LA, Albert PS, Smith ME, et al. Changes in the amount of diseased white matter over time in patients with relapsing-remitting multiple sclerosis. Neurology 1995;45:1808-1814
25. Molyneux PD, Filippi M, Barkhof F, et al. Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis. Ann Neurol 1998;43: 332-339
26. Hawkins CP, Mackenzie F, Tofts P, et al. Patterns of blood-brain barrier breakdown in inflammatory demyelination. Brain 1991;114:801-810
27. Katz D, Taubenberger JK, Cannella B, et al. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993;34: 661-669
28. Bruck W, Bitsch A, Kolenda H, et al. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol 1997;42:783-793
29. Van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412; results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997;49: 351-357
30. 1H-NMR spectroscopic studies of the brain. Neurosci Biobehav Rev 1989;13: 23-31
31. Urenjak J, Williams SR, Gadian DG, Noble M. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different cell types. J Neurosci 1993;13:981-989
32. Scolding NJ, Rayner PJ, Sussman J, et al. A proliferative adult human oligodendrocyte progenitor. Neuroreport 1995; 6:441-445
33. Davies SEC, Newcombe J, Williams SR, et al. High resolution proton NMR spectroscopy of multiple sclerosis lesions. J Neurochem 1995;64:742-748
34. Chong WK, Sweeney B, Wilkinson ID, et al. Proton spectroscopy of the brain in HIV infection: correlation with clinical, immunologic and MR imaging findings. Radiology 1993;188: 119-124
35. Gideon P, Henricksen O, Sperling B, et al. Early time course of N acetyl aspartate, creatinine and phosphocreatine and compounds containing choline in the brain after acute stroke: a proton magnetic resonance study. Stroke 1992;23:1566-1572
36. 31P magnetic resonance spectroscopy of brain degenerative cerebral disorders. Ann Neurol 1992;31:202-211
37. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996;46:373-378
38. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-399
39. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338: 278-285
40. Colello RJ, Pott U, Schwab ME. The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J Neurosci 1994;14:2594-2605
41. Kaplan MR, Meyer Franke A, Lambert S, et al. Induction of sodium channel clustering by oligodendrocytes. Nature 1997; 386:724-728
42. Meyer Franke A, Kaplan MR, Pfrieger FW, Barres BA. Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 1995;15:805-819
43. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science 1997;277:1684-1687